QOLP-03. OBSERVATIONS OF COMPLEMENTARY CANNABIS THERAPY IN MALIGNANT GLIOMA PATIENTS

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi183-vi183
Author(s):  
Nicholas Blondin
Keyword(s):  
Malignant Glioma ◽  
Median Overall Survival ◽  
Medical Marijuana ◽  
Complementary Therapy ◽  
Serious Adverse Events ◽  
Daily Group ◽  
Patient Registration ◽  
Registration Process ◽  
Recreational Use ◽  
Active Patients

Abstract INTRODUCTION As of 5/15/2021, medical marijuana programs exist in 37 states, and marijuana is legal for recreational use in 17 states. In Connecticut, the CT Medical Marijuana Program (MMP) was created in 2012 and I began certifying my patients with malignant glioma (brain cancer) for the program in 2014. I now provide data on my experience with complementary cannabis therapy. PART 1 Between 9/1/2014 and 6/1/2018, 23 patients with malignant glioma were registered in the CT MMP and received a card. Of these 23 patients, 15 patients took a daily cannabis oil supplement for at least 6 months during their treatment, and 7 patients used cannabis products only as needed. 3 patients are still alive, all in the daily cannabis oil group (41, 54 and 77 months). The median overall survival in the daily group was 22.0 months, versus 16.9 months in the as needed group. PART 2 Since 9/1/2014, 71 patients with malignant glioma were certified for the CT MMP. Of these 71 patients, 15 did not complete the patient registration process and did not receive a card for the MMP. As of 5/15/2021, of the 56 registered patients, there are 20 Active patients and 36 Inactive patients. Regarding the Inactive patients, 29 have died and 7 are alive but did not renew their card. Amongst Active patients, 4 are currently taking a daily cannabis oil supplement as a complementary therapy, and 16 are currently using cannabis products only as needed for symptoms. The 4 patients employing complementary therapy currently have a survival of 8, 31, 33, and 35 months. CONCLUSION In my experience, complementary cannabis treatment is well tolerated in malignant glioma patients, and can provide significant palliative benefit to treat insomnia and nausea. Serious adverse events attributed to cannabis products, or decreased survival, have not been observed.

scholarly journals Can the subaltern heal? Medical marijuana in Aotearoa New Zealand

2020 ◽  
pp. 144078332092514
Author(s):  
Kevin Dew ◽  
Lucas Armstrong
Keyword(s):  
New Zealand ◽  
Terminal Illness ◽  
Medical Marijuana ◽  
The State ◽  
Public Attention ◽  
The Gaze ◽  
Aotearoa New Zealand ◽  
Therapeutic Uses ◽  
Life Threatening ◽  
Recreational Use

In this article the concepts of statist medicine and subaltern therapeutics are used to provide insight into the debates over the therapeutic use of marijuana in cases of serious or terminal illness. In 2015 medical marijuana gained public attention in Aotearoa New Zealand as cases of people facing life-threatening conditions who wished to use marijuana for therapeutic purposes were given voice in the popular media. In Aotearoa New Zealand marijuana use is illegal for recreational purposes, but theoretically patients with particular conditions could gain access to medicinal forms of marijuana if health professionals, the Ministry of Health and the relevant government minister approved. This approval process is embedded within statist medicine’s regulatory regimes, where access can be provided on condition that the medication meets standards of safety and efficacy. Patients faced with the difficulty of negotiating the processes of statist medicine to access medical marijuana often reverted to illegal means of accessing the plant. Access to illegal forms of marijuana for medical purposes could be through ‘green fairies’, people who provided the plant for therapeutic purposes in a way that was distant from the criminalised recreational use of the drug obtained through ‘dealers’. The process of the state, patients and marijuana providers negotiating the regulation of therapeutic uses of marijuana provides insights into the role of statist medicine and subaltern therapeutics. The case of medical marijuana alerts us to the possibilities of other subaltern therapeutic practices that operate beyond the gaze of the state.

scholarly journals Traditional Chinese Medicine for Refractory Nephrotic Syndrome: Strategies and Promising Treatments

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Xiao-Qin Wang ◽  
Lan Wang ◽  
Yuan-Chao Tu ◽  
Yuan Clare Zhang
Keyword(s):  
Nephrotic Syndrome ◽  
Chinese Medicine ◽  
Herbal Medicine ◽  
Traditional Chinese Medicine ◽  
Kidney Diseases ◽  
Immunosuppressive Agents ◽  
Complementary Therapy ◽  
Great Promise ◽  
Serious Adverse Events ◽  
Refractory Nephrotic Syndrome

Refractory nephrotic syndrome (RNS) is an immune-related kidney disease with poor clinical outcomes. Standard treatments include corticosteroids as the initial therapy and other immunosuppressants as second-line options. A substantial proportion of patients with RNS are resistant to or dependent on immunosuppressive drugs and often experience unremitting edema and proteinuria, cycles of remission and relapse, and/or serious adverse events due to long-term immunosuppression. Traditional Chinese medicine has a long history of treating complicated kidney diseases and holds great potential for providing effective treatments for RNS. This review describes the Chinese medical theories relating to the pathogenesis of RNS and discusses the strategies and treatment options using Chinese herbal medicine. Available preclinical and clinical evidence strongly supports the integration of traditional Chinese medicine and Western medicine for improving the outcome of RNS. Herbal medicine such as Astragalus membranaceus, Stephania tetrandra S. Moore, and Tripterygium wilfordii Hook F can serve as the alternative therapy when patients fail to respond to immunosuppression or as the complementary therapy to improve therapeutic efficacy and reduce side effects of immunosuppressive agents. Wuzhi capsules (Schisandra sphenanthera extract) with tacrolimus and tetrandrine with corticosteroids are two herb-drug combinations that have shown great promise and warrant further studies.

scholarly journals Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study

2019 ◽  
Vol 49 (11) ◽  
pp. 1016-1023 ◽  
Author(s):  
Nagane Motoo ◽  
Yasuko Hayashi ◽  
Ayaka Shimizu ◽  
Masako Ura ◽  
Ryo Nishikawa
Keyword(s):  
Overall Survival ◽  
Survival Rate ◽  
Malignant Glioma ◽  
Adverse Drug Reactions ◽  
Median Overall Survival ◽  
Surveillance Study ◽  
Newly Diagnosed ◽  
Drug Reactions ◽  
Post Marketing Surveillance ◽  
Post Marketing

Abstract Objective This surveillance study was conducted to verify the post-market safety and effectiveness of bevacizumab, which was approved in Japan in 2013 for the treatment of patients with newly diagnosed and or recurrent malignant glioma. Methods This was a prospective, observational, multicenter post-marketing surveillance study. Patients with newly diagnosed or recurrent malignant glioma scheduled for bevacizumab treatment were enrolled. The incidence and severity of adverse drug reactions were calculated. The effectiveness of bevacizumab was assessed by the 1-year survival rate and the overall survival rate. Results The safety analysis set and the effectiveness analysis set each comprised 258 of the 268 enrolled patients: tumours were newly diagnosed in 80 patients (31%) and recurrent in 178 patients (68.9%). The incidence of grade ≥ 3 adverse drug reactions was 15.1%. Adverse drug reactions of special interest included 14 cerebral bleeding events and 11 infections. Of the 80 patients with newly diagnosed malignant glioma, 44 (55%) were alive throughout the 18-month observation period. The 1-year survival rate for patients with newly diagnosed glioblastoma was 78%. Median overall survival was not calculated, but 51.2% of patients were alive at the last date of observation of the last observed patient. In patients with recurrent glioblastoma, the 1-year survival rate was 38.9%, and the median overall survival was 10.2 months. Conclusions The results suggest no new safety concerns, and the effectiveness might be similar to previously reported data in clinical trials. Therefore, bevacizumab is considered as one of the treatment options for patients with malignant glioma in real-world clinical practice.

scholarly journals Omeprazole Once or Twice Daily with Clarithromycin and Metronidazole forHelicobacter pyloriEradicaiton in a Canadian Community Practice

2000 ◽  
Vol 14 (1) ◽  
pp. 27-31 ◽  
Author(s):  
Naoki Chiba ◽  
Cheryl P Marshall
Keyword(s):  
Side Effects ◽  
Triple Therapy ◽  
Community Practice ◽  
Taste Disturbance ◽  
Serious Adverse Events ◽  
Once Daily ◽  
Daily Group ◽  
First Line Therapy ◽  
H Pylori ◽  
Intent To Treat

BACKGROUND: Triple therapy for one week with omeprazole, clarithromycin and metronidazole (OCM) is accepted worldwide as a first line therapy forHelicobacter pylorieradication. It is unclear whether omeprazole needs to be given once or twice daily.OBJECTIVES: To assess the efficacy and safety of these regimens in a single-centre, Canadian practice.METHODS: Histologically provenH pylori-positive patients were treated for seven days with clarithromycin 250 mg bid and metronidazole 500 mg bid, and randomly allocated to omeprazole 20 mg either once or twice daily in this open, cohort study. Endoscopy with histology (two antrum and two body biopsies, Giemsa stain) was done four weeks or longer after the pills were completed to assessH pylorieradication.RESULTS: Whether omeprazole was given once or twice daily, eradication was high and the same in both arms. All-patients-treated eradication was 85% (39 of 46 in the omeprazole once daily group and 41 of 48 in the omeprazole twice daily group) and intent-to-treat eradication was 80% (39 of 49 in the omeprazole once daily group and 41 of 51 in the omeprazole twice daily group). Side effects were frequently seen, suffered by 65% to 69% of patients treated. However, these were mild and compliance was high, with 94% of patients taking all of their pills. Mild side effects included loose stools, taste disturbance, nausea, headache and upper or lower gastrointestinal gas. Only one patient (1%) from the omeprazole once daily arm stopped taking metronidazole due to excessive perspiring.CONCLUSIONS: In this community practice, OCM triple therapy was effective whether omeprazole was given once or twice daily. For those with financial constraint, omeprazole 20 mg once daily can be considered. The regimens were well tolerated without serious adverse events.

scholarly journals Words Can Be Deceiving: A Review of Variation among Legally Effective Medical Marijuana Laws in the United States

2014 ◽  
Vol 7 (1) ◽  
pp. 1-19 ◽  
Author(s):  
Rosalie L. Pacula ◽  
Anne E. Boustead ◽  
Priscillia Hunt
Keyword(s):  
Public Health ◽  
Health And Safety ◽  
Medical Marijuana ◽  
The United States ◽  
Us States ◽  
Legal Provisions ◽  
Public Debates ◽  
Medical Marijuana Laws ◽  
Recreational Use ◽  
Public Health And Safety

AbstractWhen voters in two US states approved the recreational use of marijuana in 2012, public debates for how best to promote and protect public health and safety started drawing implications from states’ medical marijuana laws (MMLs). However, many of the discussions were simplified to the notion that states either have an MML or do not; little reference was made to the fact that legal provisions differ across states. This study seeks to clarify the characteristics of state MMLs in place since 1990 that are most relevant to consumers/patients and categorizes those aspects most likely to affect the prevalence of use, and consequently the intensity of public health and welfare effects. Evidence shows treating MMLs as homogeneous across states is misleading and does not reflect the reality of MML making. This variation likely has implications for use and health outcomes, and thus states’ public health.

Borders Up in Smoke: Marijuana Enforcement in Nebraska After Colorado’s Legalization of Medicinal Marijuana

2015 ◽  
Vol 28 (9) ◽  
pp. 847-865 ◽  
Author(s):  
Jared M. Ellison ◽  
Ryan E. Spohn
Keyword(s):  
Criminal Justice ◽  
Law Enforcement ◽  
Medical Marijuana ◽  
State Legislature ◽  
The State ◽  
Significant Growth ◽  
Drug Arrests ◽  
Recreational Use ◽  
Transportation Route ◽  
Research And Policy

With the passage of Amendments 20 (2000) and 64 (2012), Colorado legalized the medicinal and recreational use of marijuana. Nebraskan law enforcement in border counties subsequently reported increases in arrests and reductions in jail space. In response, the Nebraska state legislature passed LR-520 to study the potential increased costs incurred by criminal justice agencies in border counties. To investigate this situation, we compare trends in drug arrests and jail occupancy across three areas: border counties, those that contain Interstate 80 (I-80) as a major transportation route, and the remaining counties in the state of Nebraska from 2000 through 2013. We found that border counties, but not necessarily those along the I-80 corridor, experienced significant growth in marijuana-related arrests and jail admissions after the expansion of the medical marijuana program in Colorado. Implications for research and policy are discussed.

scholarly journals IMT-03 CLINICAL TRIAL FOR NEWLY DIAGNOSED MALIGNANT GLIOMA WITH WT1-W10 VACCINATION

2019 ◽  
Vol 1 (Supplement_2) ◽  
pp. ii17-ii17
Author(s):  
Yu Kawanishi ◽  
Keiko Udaka ◽  
Toshio Yawata ◽  
Eiichi Nakai ◽  
Hitoshi Fukuda ◽  
...  
Keyword(s):  
Malignant Glioma ◽  
Wilms Tumor ◽  
Malignant Gliomas ◽  
Group Analysis ◽  
Treatment Resistance ◽  
Cell Vaccine ◽  
Newly Diagnosed ◽  
Serious Adverse Events ◽  
Who Grade ◽  
Vaccination Therapy

Abstract OBJECT Wilms’ tumor 1 (WT1) peptide vaccination is considered a potentially effective therapy against malignant glioma. We conducted a Phase I/II study to investigate the safety and feasibility of novel WT1 peptide (W10) vaccination therapy for patients with newly diagnosed malignant glioma. METHODS WT1 vaccination therapy was performed for patients with malignant glioma who have undergone concurrent radiotherapy and temozolomide therapy. A mixture of WT1 peptide with inactivated pertussis whole cell vaccine was injected intradermally once a week for at least 12 weeks. RESULTS Twenty-seven patients (12 men, 15 women; median 65 years) with the following tumors were enrolled: WHO grade IV (15), WHO grade III (12). PFS and OS of glioblastoma cases were 12.7 months 21.9 months, respectively. PFS of the MGMT unmethylated group was shorter than the methylated group. Interestingly enough, overall survival in the MGMT unmethylated group was not significantly different from the methylated group. Analysis of recurrent cases after immunotherapy showed decreased expression of WT1 antigen and increased Treg. They were suggested as a cause of treatment resistance. No serious adverse events were observed except for Grade 1 erythema at the injection sites. CONCLUSIONS This study of a novel WT1 vaccination therapy demonstrated safety and feasibility in the management of newly diagnosed malignant gliomas.

scholarly journals Comparative Effects of Recreational and Medical Marijuana Laws On Drug Use Among Adults and Adolescents

2020 ◽  
Author(s):  
Alex Hollingsworth ◽  
Coady Wing ◽  
Ashley Bradford
Keyword(s):  
Drug Use ◽  
Medical Marijuana ◽  
Marijuana Use ◽  
Negligible Effect ◽  
Drug Consumption ◽  
Difference In Difference ◽  
Recreational Marijuana ◽  
Medical Marijuana Laws ◽  
Recreational Use

Thirty-four states have adopted medical marijuana laws and ten states have adopted recreational marijuana laws. There is little research comparing how these two types of laws affect drug consumption of the general US population. Using a difference in difference strategy, we find that recreational laws increase past-year marijuana use by 25% among adults and by 10% among adolescents. In contrast, medical laws increase adult use by only 5% and have a negligible effect on adolescent use. We also find that recreational marijuana dispensaries are an important driver of the increase in marijuana use for adults 26 and over. Taken together, our results suggest that medical laws are not de facto recreational laws in that they succeed in mitigating recreational use, that recreational laws have broad effects on overall levels of marijuana use, and that underage marijuana use may be an important problem with existing implementations of recreational marijuana laws.

Sign in / Sign up

Export Citation Format

Share Document